Company news

Cytokinetics, Incorporated news in 2025

Cytokinetics, Incorporated's news releases, calls and decks from 2025, newest first.

View company

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

December 18, 2025

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

December 16, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

December 15, 2025

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

December 11, 2025

Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

November 16, 2025

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

November 9, 2025

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 4, 2025

Cytokinetics to Participate in November Investor Conferences

November 3, 2025

Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

October 30, 2025

Cytokinetics to Announce Third Quarter Results on November 5, 2025

October 21, 2025

Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025

September 28, 2025

Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program

September 23, 2025

Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

September 22, 2025

Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025

September 17, 2025

Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes

September 15, 2025

Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes

September 15, 2025

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025

August 30, 2025

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine

August 29, 2025

Cytokinetics to Participate in September Investor Conferences

August 26, 2025

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025

August 24, 2025

Cytokinetics Names Jim Daly to Board of Directors

August 19, 2025

Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 6, 2025

Cytokinetics to Announce Second Quarter Results On August 7, 2025

July 23, 2025

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program

June 9, 2025

Cytokinetics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

May 17, 2025

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

May 14, 2025

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

May 12, 2025

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

May 7, 2025

Cytokinetics to Hold Annual Meeting of Stockholders

May 6, 2025

Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025

Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy

April 30, 2025

Cytokinetics to Participate in May Investor Conferences

April 29, 2025

Cytokinetics to Announce First Quarter Results on May 6, 2025

April 21, 2025

Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 30, 2025

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

March 19, 2025

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo

March 16, 2025

Cytokinetics to Participate in March Investor Conferences

March 2, 2025

Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update

February 26, 2025

Cytokinetics to Announce Fourth Quarter Results on February 27, 2025

February 12, 2025

Cytokinetics Names Robert E. Landry to Board of Directors

February 10, 2025

Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 4, 2025

Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

January 29, 2025

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

January 20, 2025

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

January 12, 2025

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Calls in 2025

Decks in 2025